Melasma

Researchers are evaluating the effectiveness of two types of facial sunscreensuntinted and tintedin improving facial dark spots such as melasma, solar lentigines, and post-inflammatory hyperpigmentation. This study involves adult participants who will use the products under normal daily conditions for eight weeks to assess changes in hyperpigmentation. Participants will be assigned to one of four groups based on their skin condition and sunscreen type melasma with untinted sunscreen, melasma with tinted sunscreen, solar lentigo or post-inflammatory hyperpigmentation with untinted sunscreen, and the same conditions with tinted sunscreen. Participants will apply the assigned sunscreen to their face at least twice daily for 56 days. During the study, participants will undergo dermatological evaluations and instrumental measurements using devices like the Chroma Meter CR 400 and Visia-CR Facial Imaging Booth at baseline, 14 days, 28 days, and 56 days. Quality of life questionnaires and perception surveys will assess the impact of facial spots and product efficacy. Participants will also provide an emotional testimonial at the studys end. The total duration of participation is 8 weeks.

Researchers are evaluating whether Chitosan mouthwash can reduce the recurrence of black stains on teeth in children aged 6 to 12 years. The study aims to find out if using Chitosan mouthwash daily lowers the need for professional cleaning sessions and improves the appearance of teeth by decreasing black stain recurrence. This clinical trial is sponsored by Al-Azhar University and focuses on pediatric patients with black stains on their teeth. Participants will first undergo scaling and polishing dental cleaning, followed by a 3-month observation period. After this, scaling and polishing will be repeated, and the children will use Chitosan mouthwash daily for an additional 3 months. The study uses a crossover design where each participant serves as their own control before and after using the mouthwash. During the study, participants will visit the clinic every 6 weeks for checkups and data collection over a total of 36 weeks. Researchers will measure the recurrence of black stains as the primary outcome. The study will monitor participant adherence to the mouthwash and assess teeth appearance and stain recurrence during these visits to evaluate the mouthwashs effects.

Researchers are evaluating Autologous Adipose Cell Therapy to improve skin rejuvenation and hair restoration. This therapy aims to overcome the limitations of traditional fat grafting and dermal fillers by isolating early-stage fat cells for better distribution and longer-lasting effects. The study focuses on assessing the safety, feasibility, and effectiveness of this therapy for conditions like wrinkles, fine lines, skin elasticity loss, pigmentation, hair thinning, and hair loss. Participants will receive the Autologous Adipose Cells therapy treatment, which involves processing fat cells from their own body to enhance skin and hair appearance. The therapy is monitored by the primary investigator for up to 25 weeks to evaluate outcomes. This study includes only one treatment group receiving this biological intervention. During the study, participants will undergo various assessments including imaging, satisfaction surveys, and evaluation reports from the first visit before treatment through the last follow-up visit between weeks 16 and 25. The plastic surgeon will monitor treatment effects and safety over a six-month period. The total involvement spans from initial treatment to multiple follow-ups to track skin and hair improvements and participant satisfaction.

Researchers are studying the use of the AVAVA Device, a 1550nm Non-Ablative Fractional Laser, to treat various dermatologic conditions including acne, acne scars, wrinkles, pigment lesions, and skin texture disorders. The study aims to collect and analyze patient feedback on their overall experience with the device treatment. The primary focus is on responses to post-treatment questionnaires, while secondary measures include evaluations by physicians and patients regarding improvements and side effects. Participants will receive treatment using the AVAVA Device targeting their dermatologic condition. The study includes follow-up periods at 3, 6, and 12 months after the final treatment to assess outcomes. During these times, trained dermatologists will review before and after images, and both physicians and subjects will complete satisfaction and clinical improvement scales. The treatment process involves digital photography and adherence to specific skincare and sun exposure guidelines. Throughout the study, participants will complete questionnaires immediately after treatment and during follow-up visits to report their experience and tolerance of the procedure, including pain levels. Researchers will monitor the skins response and improvements over time through imaging and clinical assessments. The study requires participants to comply with study instructions, maintain consistent skincare, and attend scheduled visits. The total participation duration spans from initial treatment through 12 months of follow-up.

Researchers are studying the effectiveness and tolerability of a hybrid non-ablativeablative laser called the Sciton Halo for treating acne scars, especially in people with darker skin tones Fitzpatrick IV and V. Acne scarring can negatively impact quality of life and mental health, and current treatments have limited evidence for their benefit. This study focuses on improving acne scars with this newer laser technology that combines two wavelengths for targeted skin treatment. Participants receive treatment with the Sciton Halo hybrid fractional laser in two groups based on skin type. Each group will have 23 participants with either Fitzpatrick skin types IV-V or I-III. At the first visit, participants provide consent, receive education on the procedure and sun care, and are given sunscreen. They may be prescribed hydroquinone or retinol to prevent hyperpigmentation, starting treatment after one month if they choose. Treatment involves up to three laser sessions, with the number depending on improvement. Before and after photos are taken at each session, and participants complete quality of life and satisfaction surveys. During the study, participants will be monitored regularly up to nine months. Assessments include changes in acne scar severity, clinician and patient evaluations of improvement, skin texture, pigmentation, and overall satisfaction. Researchers will also track adherence to skin care, sunscreen use, sun avoidance, side effects, and pain. The study aims to measure both clinical outcomes and patient experiences over time to evaluate the lasers impact on acne scars in skin of color.

Researchers are evaluating a new cosmetic formula to treat facial hyperpigmentation caused by three conditions mild to moderate melasma, mild to moderate acne-induced post-inflammatory hyperpigmentation, and solar lentigo. This open, single-center study aims to assess the products effectiveness, cosmetic acceptability, and its impact on reducing stigma associated with these skin conditions. The study follows ethical guidelines and good clinical practices to ensure proper conduct and data analysis. The study involves applying the tested product twice daily, in the morning and evening, along with using sunscreen in the morning and at midday for three months. Participants are grouped based on their specific type of hyperpigmentation melasma, acne-induced hyperpigmentation without active acne, or solar lentigo. Each participant will use the product under normal conditions, with before-and-after comparisons to evaluate changes. Participants will be assessed at the start and after 84 days to measure skin changes using various pigmentation scores specific to each condition. Researchers will also use colorimetry to quantify skin color changes. Safety data will be recorded but not statistically analyzed. The study expects to include about 20 patients per group and will observe participants throughout the three-month treatment period to monitor efficacy and tolerability.

Melasma is a common chronic skin condition causing brown to gray-brown patches, primarily on the face, especially in adult women with certain skin types. This research compares two treatments for facial melasma injectable platelet-rich fibrin i-PRF, a platelet concentrate from the patients own blood, and intradermal tranexamic acid TA, a drug that may reduce pigmentation. The study aims to assess which treatment is safer and more effective for improving melasma. Adult female patients with mild to moderate symmetrical facial melasma will participate. Each participants face will be split one side will receive i-PRF injections prepared from their blood, and the other side will receive intradermal tranexamic acid injections. Both treatments will be given in five sessions spaced two weeks apart, alongside instructions to use sunscreen and avoid other facial treatments. Participants will be evaluated before treatment and 90 days later using various measures such as the modified Melasma Area and Severity Index mMASI, skin imaging with the Antera 3D camera, physician assessments, patient satisfaction, and quality of life questionnaires. Safety will be monitored by recording any side effects like pain, redness, swelling, or bruising. This study is designed to provide detailed comparisons of efficacy and safety between these two treatments.

Researchers are evaluating if metformin can help reduce the dark patches of melasma in Latin American women. This clinical trial aims to determine whether taking metformin daily for three months improves melasma, by comparing two different doses to see if either dose helps with this skin condition. The study is sponsored by the University of Puerto Rico and focuses on adult women aged 21 years and older. Participants will take oral metformin tablets starting at 500 mg once daily for the first four weeks. If participants tolerate the medication well, their dose will increase to 500 mg twice daily for the remaining eight weeks. During the trial, participants are asked to avoid other melasma treatments and use sunscreen with SPF 30 or higher daily. The study involves two clinic visits one at the beginning and one at the end of the 12-week period. Throughout the study, researchers will monitor changes in the modified Melasma Area and Severity Index mMASI score from the start to week 12 to assess treatment impact. Participants will receive a phone call from the research team to check on their progress and any side effects. The total participation time spans three months, with evaluations at the start and conclusion of the treatment period.

Researchers are evaluating whether some women aged 60 or older with early breast cancer can safely skip radiation therapy after breast conserving surgery. The study focuses on patients with low-risk breast cancer, aiming to identify who might avoid radiation without a high chance of cancer returning locally. This is important because radiation can cause both short-term and long-term side effects, and not all patients gain the same benefit from it. The trial compares two approaches one group will receive partial breast irradiation using external beam radiation at a dose of 40 Gy divided into 15 fractions over 3 weeks, while the other group will receive no radiation therapy. This comparison will help determine if radiation can be omitted safely in selected low-risk patients. The study is randomized and does not use any masking or blinding. Participants will be monitored over 10 years to measure invasive local recurrence of cancer as the primary outcome. Researchers will also track regional lymph node recurrence, distant failure, and death. Patients will have regular assessments to evaluate these outcomes and any side effects. The total follow-up period ensures long-term safety and effectiveness data for the treatment approaches.

Researchers are studying changes in facial pigmentation and skin microbiome after applying topical almond oil compared to 2% hydroquinone cream. This study involves 50 premenopausal women with specific skin types and aims to evaluate these treatments over a 4-month period to understand their effects on skin appearance and microbial balance. Participants will be randomly assigned to one of two groups one applying almond oil nightly and the other applying 2% hydroquinone cream nightly. The treatments will be used throughout the study duration, which spans from consent through five visits including assessment visits for skin pigment, hydration, and sebum rates. During the study, participants will undergo imaging and measurements to monitor facial pigment intensity, skin hydration, sebum excretion, microbiome diversity, and redness. Subjective tolerability will also be assessed. The study includes a two-week washout from certain topical products before visits, and adherence to study treatments and restrictions will be monitored over the total 4-month participation period.